ArticleCancer2021

Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.

Thomas G Martin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.